Turbine Raises $25 Million Series B to Scale Virtual Cell Platform and Enter Immunology

New updates have been reported about Turbine.

Turbine has secured a $25 million Series B round to accelerate deployment of its AI-powered virtual cell platform and expand beyond oncology into immunology in partnership with a top 10 pharmaceutical company. The funding, led by Interactive Venture Partners with participation from Beiersdorf and existing backers such as MSD Global Health Innovation, Accel, and Mercia, strengthens Turbine’s balance sheet and supports broader adoption across biopharma R&D.

The company plans to use the capital to virtualize additional assays across discovery and translational medicine, enhancing its lab-in-the-loop system that generates proprietary perturbation datasets to refine its foundational virtual cell model for new tissue and assay types. Turbine will deliver these capabilities via its Virtual Lab, a no-code environment already integrated into pharma workflows, enabling partners like MSD, AstraZeneca, and Bayer to run in silico experiments at scale and prioritize only the highest-confidence hypotheses for wet-lab testing.

Strategically, Turbine is moving beyond its core oncology franchise by launching its first immunology-focused collaboration with a major global pharma, which will train Turbine’s virtual assays on proprietary immune cell datasets to map immune pathway mechanisms and optimize drug combinations. This initiative is designed to address the complexity and combinatorial explosion of immunology regimens by using simulation to identify promising combinations and patient subgroups before costly clinical validation, which CEO and co-founder Szabolcs Nagy positions as essential to rationally designing next-generation combination therapies.

The Beiersdorf participation signals optionality for Turbine’s technology beyond traditional drug discovery, as the skincare group sees potential to use virtual cell models to study how active ingredients interact with skin biology, conditions, and safety endpoints. With backing from deep-pocketed strategic and financial investors and a growing base of top-tier pharma partners, Turbine is positioning its platform as infrastructure for virtualizing biological experiments, aiming to compress development timelines, improve clinical translatability, and turn biology into a more predictable, engineering-driven discipline.